Y-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue

MT Newswires Live

Jan 11, 2025

Y-mAbs Therapeutics (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.

The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.

Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.

Shares of the company were down by nearly 6% in recent Friday trading.

Price: 7.01, Change: -0.38, Percent Change: -5.14

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502899682"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502899682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502899682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-11 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502899682","market":"sg","top_or_hot":-1,"title":"Y-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue","media":"MT Newswires Live","content":"<html><body><p> Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.</p><p>The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.</p><p>Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.</p><p>Shares of the company were down by nearly 6% in recent Friday trading.</p><p>Price: 7.01, Change: -0.38, Percent Change: -5.14</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-11 00:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.</p><p>The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.</p><p>Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.</p><p>Shares of the company were down by nearly 6% in recent Friday trading.</p><p>Price: 7.01, Change: -0.38, Percent Change: -5.14</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YMAB","symbol_name":"Y-mAbs Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502899682","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502899682","pubTimestamp":1736525313,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Y-mAbs Therapeutics (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.The company expects a reduction in its current staffing of up t","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"YMAB":"Y-mAbs Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Y-mAbs Therapeutics建立两个新业务部门，报告2024年初步净收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9,"LENZ":1},"content_text":"Y-mAbs Therapeutics (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.Shares of the company were down by nearly 6% in recent Friday trading.Price: 7.01, Change: -0.38, Percent Change: -5.14","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}